48 related articles for article (PubMed ID: 11462982)
1. Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release.
Morese PA; Anthony N; Bodnarchuk M; Jennings C; Martin MP; Noble RA; Phillips N; Thomas HD; Wang LZ; Lister A; Noble MEM; Ward RA; Wedge SR; Stewart HL; Waring MJ
J Med Chem; 2023 Sep; 66(17):12324-12341. PubMed ID: 37647129
[TBL] [Abstract][Full Text] [Related]
2. A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure-Activity Relationship.
Yadav TT; Moin Shaikh G; Kumar MS; Chintamaneni M; Yc M
Front Chem; 2022; 10():861288. PubMed ID: 35769445
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of targeted and immune based anti-cancer therapies.
Seebacher NA; Stacy AE; Porter GM; Merlot AM
J Exp Clin Cancer Res; 2019 Apr; 38(1):156. PubMed ID: 30975211
[TBL] [Abstract][Full Text] [Related]
4.
Kimura H; Okuda H; Ishiguro M; Arimitsu K; Makino A; Nishii R; Miyazaki A; Yagi Y; Watanabe H; Kawasaki I; Ono M; Saji H
ACS Med Chem Lett; 2017 Apr; 8(4):418-422. PubMed ID: 28435529
[TBL] [Abstract][Full Text] [Related]
5. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.
Schroeder RL; Stevens CL; Sridhar J
Molecules; 2014 Sep; 19(9):15196-212. PubMed ID: 25251190
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
Wu J; Chen W; Xia G; Zhang J; Shao J; Tan B; Zhang C; Yu W; Weng Q; Liu H; Hu M; Deng H; Hao Y; Shen J; Yu Y
ACS Med Chem Lett; 2013 Oct; 4(10):974-8. PubMed ID: 24900594
[TBL] [Abstract][Full Text] [Related]
7. New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Behera R; Thomas SM; Mensa-Wilmot K
Antimicrob Agents Chemother; 2014; 58(4):2202-10. PubMed ID: 24468788
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffolds.
Katiyar S; Kufareva I; Behera R; Thomas SM; Ogata Y; Pollastri M; Abagyan R; Mensa-Wilmot K
PLoS One; 2013; 8(2):e56150. PubMed ID: 23437089
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of New 6-{[ω-(Dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones and Evaluation of their Anticancer and Antimicrobial Activities.
Berest GG; Voskoboynik OY; Kovalenko SI; Nosulenko IS; Antypenko LM; Antypenko OM; Shvets VM; Katsev AM
Sci Pharm; 2012; 80(1):37-65. PubMed ID: 22396903
[TBL] [Abstract][Full Text] [Related]
10. In silico QSAR studies of anilinoquinolines as EGFR inhibitors.
Pasha FA; Muddassar M; Srivastava AK; Cho SJ
J Mol Model; 2010 Feb; 16(2):263-77. PubMed ID: 19590909
[TBL] [Abstract][Full Text] [Related]
11. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.
Mishani E; Abourbeh G; Eiblmaier M; Anderson CJ
Curr Pharm Des; 2008; 14(28):2983-98. PubMed ID: 18991714
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.
Pal A; Glekas A; Doubrovin M; Balatoni J; Namavari M; Beresten T; Maxwell D; Soghomonyan S; Shavrin A; Ageyeva L; Finn R; Larson SM; Bornmann W; Gelovani JG
Mol Imaging Biol; 2006; 8(5):262-77. PubMed ID: 16897320
[TBL] [Abstract][Full Text] [Related]
13. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.
Shen Q; Brown PH
J Mammary Gland Biol Neoplasia; 2003 Jan; 8(1):45-73. PubMed ID: 14587863
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.
Citri A; Alroy I; Lavi S; Rubin C; Xu W; Grammatikakis N; Patterson C; Neckers L; Fry DW; Yarden Y
EMBO J; 2002 May; 21(10):2407-17. PubMed ID: 12006493
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
Smaill JB; Showalter HD; Zhou H; Bridges AJ; McNamara DJ; Fry DW; Nelson JM; Sherwood V; Vincent PW; Roberts BJ; Elliott WL; Denny WA
J Med Chem; 2001 Feb; 44(3):429-40. PubMed ID: 11462982
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
18. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
Tsou HR; Mamuya N; Johnson BD; Reich MF; Gruber BC; Ye F; Nilakantan R; Shen R; Discafani C; DeBlanc R; Davis R; Koehn FE; Greenberger LM; Wang YF; Wissner A
J Med Chem; 2001 Aug; 44(17):2719-34. PubMed ID: 11495584
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.
Wakeling AE; Barker AJ; Davies DH; Brown DS; Green LR; Cartlidge SA; Woodburn JR
Breast Cancer Res Treat; 1996; 38(1):67-73. PubMed ID: 8825124
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
